- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Julie Maréchal-Jamil: Biosimilar Adalimumab in Europe
Julie Maréchal-Jamil, director of biosimilars policy and science at Medicines for Europe, describes early experience with biosimilar adalimumab in Europe.
Transcript
What has been the impact of biosimilar adalimumab in the European marketplace?
For adalimumab, I think what’s worth highlighting—before we talk about the impact or anything, I think—for adalimumab, it’s a very unique situation. It’s something we’ve never seen before, and it’s rather unlikely that we’re going to see any such synchronicity in the launches.
For now, it’s still early days. We’re 3 months in. If you look at the overall European use of the adalimumab options, I think it’s probably been launched in half of the countries. In Germany, it’s been used to a higher extent over a shorter period than the previous biosimilars, showing greater confidence, greater acceptance.
It’s true that governments were very keen, and I think another unique feature of adalimuamb is not so much again the impact, but the way to the launches. While some governments have been preparing a lot for the lunches, the introduction of biosimilars, with adalimumab, it was extreme preparation. We’ve seen in the [United Kingdom] or Denmark really intense preparation, looking at all the features of the system that needed to be ready in time for the successful uptake, launches, introduction, and so on.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Q&A: Dr Kimberly Maxfield Explains How BsUFA III Will Advance the US Biosimilar Industry
December 20th 2023At AMCP Nexus, Kimberly Maxfield, PhD, pharmacologist at the FDA, delved into how the third reauthorization of the Biosimilar User Fee Act (BsUFA III) will shape the American biosimilar market and improve development efficiency over the next few years.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
